An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued
Key Insights
- The projected fair value for Cansortium is US$0.13 based on 2 Stage Free Cash Flow to Equity
- Cansortium's US$0.095 share price signals that it might be 26% undervalued
- The US$0.83 analyst price target for TIUM.U is 543% more than our estimate of fair value
In this article we are going to estimate the intrinsic value of Cansortium Inc. (CSE:TIUM.U) by estimating the company's future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Believe it or not, it's not too difficult to follow, as you'll see from our example!
We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.
See our latest analysis for Cansortium
Crunching The Numbers
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) estimate
2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | |
Levered FCF ($, Millions) | US$9.00m | US$5.67m | US$4.24m | US$3.51m | US$3.10m | US$2.87m | US$2.73m | US$2.66m | US$2.62m | US$2.61m |
Growth Rate Estimate Source | Analyst x1 | Est @ -36.96% | Est @ -25.34% | Est @ -17.21% | Est @ -11.52% | Est @ -7.54% | Est @ -4.75% | Est @ -2.80% | Est @ -1.43% | Est @ -0.47% |
Present Value ($, Millions) Discounted @ 10% | US$8.2 | US$4.7 | US$3.2 | US$2.4 | US$1.9 | US$1.6 | US$1.4 | US$1.2 | US$1.1 | US$1.0 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$27m
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.8%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 10%.
Terminal Value (TV)= FCF2032 × (1 + g) ÷ (r – g) = US$2.6m× (1 + 1.8%) ÷ (10%– 1.8%) = US$31m
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$31m÷ ( 1 + 10%)10= US$12m
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$38m. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of US$0.1, the company appears a touch undervalued at a 26% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
The Assumptions
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Cansortium as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 10%, which is based on a levered beta of 1.426. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Cansortium
- Debt is well covered by cash flow.
- Interest payments on debt are not well covered.
- Shareholders have been diluted in the past year.
- Forecast to reduce losses next year.
- Has sufficient cash runway for more than 3 years based on current free cash flows.
- Good value based on P/S ratio and estimated fair value.
- Significant insider buying over the past 3 months.
- Not expected to become profitable over the next 3 years.
Looking Ahead:
Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. What is the reason for the share price sitting below the intrinsic value? For Cansortium, there are three additional aspects you should further research:
- Risks: Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Cansortium , and understanding these should be part of your investment process.
- Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for TIUM.U's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the CNSX every day. If you want to find the calculation for other stocks just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:TIUM.U
Cansortium
Through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas.
Slightly overvalued with imperfect balance sheet.